OBJECTIVES: Platelet dysfunction is one of the major haematological disturbances of cardiopulmonary bypass (CPB). In addition, cyanosis is known to cause further coagulation disturbances.
INTRODUCTION
Abnormal platelet function is one of the haematological features observed in congenital heart disease (CHD). Mauer [1] was one of the first to describe this impairment in platelet function in severely cyanotic children. He described a defect in the release of adenosine diphosphate (ADP) from platelets with normal amounts of ADP in the granula [1] . The main underlying mechanism hereby seems to be the longstanding effect of hypoxia and erythrocytosis.
The surgical correction of CHD in infants under 1 year necessitates the transfusion of multiple blood products. This requirement is due to the extremes of haemodilution, temperature and complexity of surgery involving multiple suture lines along major vessels. Besides heparin management, platelet dysfunction has been considered a major culprit in postoperative bleeding during congenital cardiac surgery. Both platelet function and the coagulation system undergo maturational changes that may have a major effect on blood loss and transfusion requirements. Two smaller studies have previously examined the relationship between platelet function and postoperative bleeding in paediatric patients and found no association [2, 3] . Following these earlier studies, we present our data on a group of neonates and infants, focusing on the effects of cyanosis on platelet aggregation. The primary endpoint was the association between baseline platelet aggregation and cyanosis in neonates and infants with congenital heart disease (CHD) as measured by multiple electrode aggregometry (MEA, MULTIPLATE™, Verum Diagnostica, Munich, Germany). Neonatal platelets are influenced by maturational changes while infantile platelets are altered by chronic activation and exhaustion. Our secondary end-points were whether platelet aggregation is different between these two groups during the perioperative course of the first 24 h and has any relation to postoperative blood losses. Postoperative blood losses were quantified by chest tube drainage (CTD), and the necessity for blood transfusion was measured by the total number of exposures to blood products. We also attempted to define the predictive value of perioperative MULTIPLATE™ measurements on blood loss and transfusion requirements.
METHODS
The study was approved by the ethics committee of the Medical Faculty, Technische Universität München, Germany (reference number 2211/08). Written parental consent was obtained in all cases. We included 110 children under 1 year of age, undergoing cardiac surgery with the use of cardiopulmonary bypass (CPB). Cyanosis was defined as SpO 2 <90%. Exclusion criteria were preoperative coagulopathies as defined by pathological international normalized ratio (INR) and partial thromboplastin time (PTT) levels outside the laboratory norm and any known platelet inhibition. Anaesthesia was performed according to our standard practice with midazolam, sufentanil and pancuronium. Prostaglandin E2 (PGE 2 ) infusions were continued from the intensive care unit (ICU) at 10 ng/kg/h until the beginning of CPB. A non-coated bypass circuit was utilized with either a Dideco D100 for neonates less than 5 kg (Sorin Group, Milan, Italy) or a Terumo Baby RX oxygenator (Terumo Cardiovascular Systems Corporation, Ann Arbor, MI, USA). The CPB priming fluid included Ringer's acetate, 5000 IU of heparin, 100-150 ml of washed packed red blood cell (PRBC), 100-150 ml of fresh frozen plasma (FFP) and sodium bicarbonate. Prime volume reduction led to total prime volumes of 330 ml. No synthetic colloids were used at any point in time. About 500 IU/kg of heparin was given to achieve an activated clotting time (ACT) of greater than 480 s and maintained. Epsilon aminocaproic acid as an antifibrinolytic in a regimen adapted from Ririe et al. [4] was used. After routine modified ultrafiltration, protamine was administered in a heparin to protamine ratio of 1 : 1.3. Additional protamine was given based on ACT measurements or residual heparin effects in the thromboelastography (Rotem™, TEM International, Munich, Germany). Platelet transfusions were never given before full heparin reversal was accomplished after CPB, and the decision to transfuse was based on Rotem™ values, platelet counts less than 80 000/µl and clinical bleeding. The haematocrit was kept >25% during CPB and >35% in patients with a residual cyanosis. An INR >1.2 was corrected with additional FFP. Blood loss at 6 and 24 h postoperatively and the amount of allogeneic blood products used intra-and postoperatively were recorded. Blood samples were obtained from an arterial catheter after the induction of anaesthesia and insertion (Baseline BL), 10 min after protamine administration (Prot), upon arrival in the ICU (ICU) and on the morning of postoperative day 1 (POD 1). For the MULTIPLATE™ (Dynabyte Medical, Munich, Germany) measurements, blood was drawn into 2-ml hirudin prefilled tubes (25 µg/ml) and rested for 30 min at room temperature before analysis as recommended by the manufacturer (time window 30-240 min). We performed testing using adenosine diphosphate (ADP Test 0.2 mM, Instrumentation Laboratory, Munich, Germany) and thrombin-related activation peptide (TRAP)-activating agents (TRAP test 1 mM, Instrumentation Laboratory). Technical details can be found elsewhere. Results are presented as area under the curve and the anaesthesiologist at the bedside was blinded to the results. Platelet counts and routine laboratory parameters [haemoglobin (Hb), INR, PTT, fibrinogen] were measured at the according time points.
STATISTICS
Descriptive and explorative statistics were used for data analysis. The distribution of qualitative measures is presented by absolute and relative frequencies. Depending on the cell counts of corresponding contingency tables, group comparisons were performed by χ 2 tests or Fisher's exact tests. Mean ± SD and median (interquartile range) are given for normally and non-normally distributed data, respectively. Accordingly, group comparisons were performed by t-tests and Mann-Whitney U-tests. The relation of quantitative measures was assessed by Spearman's correlation coefficient. All statistical testing was performed on an explorative significance level of 0.05. Analysis was conducted using PASW Statistics for Windows Version 21.0 (IBM Corporation, Somer, NY, USA). Table 1 summarizes the demographic and surgical data. The severity of surgical intervention was comparable. No significant Data are presented as median (interquartile range 25-75%) or absolute frequency (percentage). *P < 0.05 cyanotic versus acyanotic within age group. CPB: cardiopulmonary bypass; PGE2: prostaglandin E2; RACHS-1: risk-adjusted congenital heart surgery core; DHCA: deep hypothermic circulatory arrest.
RESULTS
differences between the two neonatal groups were observed except for shorter bypass and aortic cross-clamp times in cyanotic neonates. In the infant group, only 37% of cyanotic children required aortic clamping compared with 100% in the acyanotic group. There was a weak correlation of haemoglobin on baseline platelet function [Spearman Rho for Hb vs ADP (R = −0.401*, P = .025) and TRAP (R = −0.368*, P = 0.046)]. Cyanosis did not have any statistically significant effect on platelet function (Table 2 ).
However, in the infant group, baseline TRAP values for the acyanotic infant groups were lower than in the cyanotic infant [83 (64-96) U vs 95 (79-101) U], though not statistically significant (P = 0.075). During the time on CPB, in vitro platelet function decreased significantly and recovered only partially by the end of Day 1 without any detectable influence of cyanosis. As for the laboratory values (Table 3) , cyanotic infants had significantly higher baseline values of haemoglobin (P = 0.002) and fibrinogen (P = 0.018). The coagulation profile was not statistically significantly different among acyanotic and cyanotic groups except for a higher INR at baseline in the cyanotic neonatal group. Transfusion requirements expressed as total number of exposures were similar within groups except for a statistically significant higher transfusion rate of PRBCs in the cyanotic newborn group (Table 4) . Postoperative chest tube losses and the number of donor exposures were not statistically different within groups and not associated to platelet function or cyanosis. Overall baseline platelet function was a weak predictor of postoperative blood loss (Table 5 ). In neonates, ADP after protamine was related to CTD at 6 h after surgery and total blood product exposure in the first 24 h after ICU admission. In the same group, TRAP activity was weakly related to blood component exposure. For the infant group, ADP at the time of protamine infusion and upon ICU arrival correlated significantly with total blood exposure while TRAP was not significantly related to CTD and transfusion requirements.
DISCUSSION
We tested the association of cyanosis to baseline platelet aggregation during paediatric cardiac surgery and the time course of platelet function using the MULTIPLATE™ assay. The baseline platelet function was not significantly different in neonates and infants with or without cyanosis, and was a weak predictor of clinical blood transfusion requirements and postoperative CTD in cardiac surgery for children under 1 year of age.
Platelet function and testing in neonates
Platelet function of neonates is different from adults. Adhesion receptors are present early in foetal life, but become only fully functional beyond infancy [5] . The limiting factors of platelet function in neonates are a reduced activation and secretion. Further, receptor-mediated signal transduction is reduced, leading to less Ca 2+ mobilization and reduced granule content secretion [6] . At what point in time these changes disappear is controversial, but they might reach values similar to adult activity as early as 10-14 days of age [7] . We did not separate our neonatal group at this age point following evidence from Straub et al. [8] that showed no significant difference in terms of platelet activity in neonates <9 or >14 days of age. Further differences in the aggregation of neonatal platelets are decreased epinephrine-and collagen-induced activity [9] . Additionally, thrombin-induced platelet aggregation is less potent. This is reflected in the lower limits of normal for the MULTIPLATE™ test with thrombin activation (TRAP-6), the cause being the decreased protease-activated receptor 1 (PAR-1) expression on the platelets, a major constituent for thrombininduced activation at low levels of thrombin and the primary pathway for TRAP-6 induction [10] . In the absence of GP IIb/IIIa inhibitors, the TRAP test 'represents the natural aggregation potential of the platelets' [2] .
We used whole blood aggregometry as a well-established measurement of platelet function. It is considered to be one of the most sensitive measures of platelet function during cardiac surgery [11, 12] , and the results are comparable with the gold standard of light transmission aggregometry [13] . Using a functional method rather than surface markers may likewise be beneficial. Surface markers such as P-selectin may be lost during the course of CPB, but platelets still remain functional in vivo, which is better reflected using the MULTIPLATE™ [14] .
The MULTIPLATE™ analyser has been used in healthy neonates and children to establish reference values for TRAP and ADP testing [15] . These are slightly higher than the values we found, owing to the inclusion of healthy children up to 1 year of age in the reference group by Halimeh et al. [15] . Therefore, our numbers could be considered reference values for neonates and infants with CHD with and without cyanosis ( Table 2) .
Association of cyanosis to platelet function and laboratory values
Ranucci et al. [2] examined the TRAP test during paediatric cardiac surgery. In their 22 patients, not separated for cyanosis, TRAP values were 'subnormal at baseline' [2] and further declined until ICU admission. In children under the age of 7, Hofer et al. [3] described a decreased baseline platelet aggregation in acyanotic children compared with the age-adjusted norm and the cyanotic group that decreased further during surgery followed by a slow recovery over several days. In children under the age of 15, Bønding Andreasen [16] saw no effect of cyanosis. Nonetheless, both described a reduction in perioperative platelet aggregation. Using our larger collective and separating the neonatal from the infant group, painted a somewhat different picture from these previous studies. Cyanosis had no statistically significant relation to platelet count and function except for the acyanotic infant group where a non-significantly decreased platelet function at baseline was detected. This effect disappeared throughout the perioperative course, and was not reflected in the subsequent blood loss or transfusion requirements. Similar findings have been described by Mauer et al. [1] . Finally, we saw a weak correlation between haemoglobin and platelet function at baseline in the cyanotic newborn group, but not beyond. We might also speculate that the loss of function in the acyanotic infants may be secondary to the longstanding activation and exhaustion of granules in high flow shunt lesions such as atrial or ventricular septal defects [1, 17] . The effect of cyanosis on platelet function and blood loss may not be eminent yet in children under 1 year of age despite an already rising haematocrit in the cyanotic infant group as a sign of chronic hypoxaemia (Table 3) . When these changes ultimately occur is unknown, but Ismail et al. [17] showed that at a median age of 3.5 years, significant changes in platelet function had occurred.
Postoperatively, coagulation end-points within all groups were similar, eliminating different treatment regimens and differences in platelet function due to unmeasured covariates. These observations did not affect the total number of exposures to blood products and do not appear to be of any clinical significance.
Time course of platelet activity on cardiopulmonary bypass
The platelet function defect of CPB has been known for quite some time. Additionally, the course of paediatric platelet activity on CPB has been well described by Ichinose et al. [18] . He noted a loss of platelet adhesion receptors GPIb, also known as the von Willebrand co-factor, and P-selection. At the end of CPB, 75% of baseline values were reached that continued to decline further for the next 1-2 h. Cyanotic patients presented with persistently lower values, which is possibly a sign of early exhaustion.
In our study, we tested platelets after in vitro activation with ADP and TRAP. In this approach, loss of surface receptor activity throughout the course of CPB can only indirectly be seen as a loss of aggregation. Our pattern and time course was representative of these aforementioned studies and revealed a progressive functional loss over the time on CPB with a trend towards recovery after protamine. By postoperative day 1, preoperative values were still not reached in our patient groups except for the acyanotic neonates. This excludes a significant effect of the lower platelet count and fibrinogen on platelet function on day 1. Again, no effect of cyanosis was seen.
Platelet function, postoperative chest tube drainage and donor exposures
The postoperative platelet dysfunction after CPB lasts up to 24 h. Baseline values were not strongly associated with transfusion requirements or CTD underlining the fact that bleeding is often related to surgical factors, and is multifactorial. A few time points were statistically significant for the prediction of blood loss. However, these are probably better suited as warning flags rather than strong clinical predictors since they occur late into the clinical course around the time of heparin reversal with protamine, which induced a second temporary disturbance of platelet aggregation [19, 20] . Ranucci et al. [2] and Hofer et al. [3] examined the relationship between the MULTIPLATE™ and postoperative bleeding in children and found a statistically weak correlation as well. This is opposed to recent studies in adult cardiac surgery patients [11, 21, 22] . In adults, medication-induced platelet dysfunction is more prevalent, the degree of haemodilution is less and the complexity of surgery is lower than in children. Taken together, MULTIPLATE™ analysis alone might not be a valuable tool for the prediction of postoperative blood losses in paediatric patients. However, as Ranucci et al. [2] pointed out, the MULTIPLATE™ in conjunction with the thromboelastography might be a valuable tool for intraoperative decision-making to transfuse platelets. This is our current practice and awaits further validation.
Limitations of our study
Our study is limited to infants under 1 year of age. Furthermore, it encompasses a typical western population from a dataset of wellmonitored patients, excluding extremes of cyanosis with further marked disease. PGE 2 is also known to inhibit platelet function in a dose-dependent manner. However, PGE2 rapidly disappears from the blood and after 4 min only 0-0.5% of an injected dose remain [23] . We did not find significant differences in platelet function of neonates on or off PGE2 infusions (data not shown). Since the samples were rested for 30 min at room temperature, it is questionable whether any changes in platelet function due to PGE2 can be detected by the MULTIPLATE™ analyser. MEA is also a static test and does not reflect the effect of any shear stress or endothelium on platelet function. Furthermore, the assay is influenced by all cellular and plasmatic components [24] . A lower limit of 75 000/μl for the platelet count is recommended, and we excluded lower values from our analysis. The haematocrit at both ends of the scale is also influential [24] . The optimal haematocrit for platelet function is around 30%, and higher or lower values depress the platelet function, but even in the neonatal group, the nadir of haematocrit was above 25% at all times. Further, we did consider for gestational age, which has been shown to influence the platelet function of neonates at term [25] , but only before Day 5 of life. Our youngest study subjects (n = 2) were 4 days old, leaving these early developmental changes negligible. Likewise, gender has no influence on testing in children [15] .
CONCLUSIONS
In summary, we were unable to observe any clinically relevant association of cyanosis to baseline platelet aggregation in children under 1 year of age. Baseline values were similar to the adult norm except for lower baseline values of aggregation in the acyanotic infant group. Blood loss and transfusion requirements were not strongly associated with cyanosis, but the cyanotic neonates required more PRBC transfusions without any effect on the total number of exposures to blood products. In our study population, we were unable to observe a clinically relevant impact of chronic hypoxaemia on platelet aggregation during the first year of life. Overall baseline platelet function as measured with the MULTIPLATE™ only weakly correlated with postoperative blood loss. However, MULTIPLATE™ might be helpful to individualize the transfusion decision after CPB depending on a meticulous heparin management and point-of-care diagnostics (thromboelastography, multiple electrode aggregometry). We conclude that children under 1 year require no age-specific approach with regard to platelet transfusions, independent of cyanosis.
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